All In Biotech

Drug Trial Radar · NCT02344290

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE

Last checked: Nov 20, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 7,769 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,769

Actual

Start

Mar 26, 2015

Primary completion

Aug 21, 2023

Study completion Aug 21, 2023

Sponsor

Sponsor type
NIH
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Kowa Pharmaceuticals America, Inc.; Gilead Sciences; Massachusetts General Hospital; NEAT ID Foundation
First posted
Jan 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART). The REPRIEVE trial consisted of two parallel identical protocols: * REPRIEVE (A5332) was funded by the NHLBI, with additional infrastructure support provided by the NIAID, and was conducted in U.S and select international sites (approximately 120 sites in 11 countries). * REPRIEVE (EU5332) was co-sponsored by NEAT ID and MGH, and was conducted at 13 sites in Spain.

Conditions

  • HIV
  • Cardiovascular Diseases

Interventions

  • PitavastatinDrug

    One tablet (4 mg) taken once daily, orally with or without food

  • PlaceboDrug

    One tablet taken once daily, orally with or without food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rate of Major Adverse Cardiovascular Event (MACE)Time frame: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).

Locations

137 sites in 13 countries. Site status is shown where the registry gives one.

  • Alabama CRS*

    Birmingham, Alabama

  • University of Arizona CRS

    Tucson, Arizona

  • University of Southern California CRS*

    Los Angeles, California

  • UCLA CARE Center CRS*

    Los Angeles, California

  • Mills Clinical Research CRS

    Los Angeles, California

  • VA West Los Angeles Medical Center CRS

    Los Angeles, California

  • Los Angeles LGBT Center CRS

    Los Angeles, California

  • Eisenhower Health Center at Rimrock CRS

    Palm Springs, California

  • Stanford AIDS Clinical Trials Unit CRS

    Palo Alto, California

  • UCSD Antiviral Research Center CRS*

    San Diego, California

  • Ucsf Hiv/Aids Crs*

    San Francisco, California

  • Harbor-UCLA CRS*

    Torrance, California

  • University of Colorado Hospital CRS*

    Aurora, Colorado

  • Denver Public Health CRS

    Denver, Colorado

  • Yale University CRS

    New Haven, Connecticut

  • VA Connecticut Healthcare System CRS

    West Haven, Connecticut

  • Whitman-Walker Health CRS

    Washington D.C., District of Columbia

  • Georgetown University CRS (GU CRS)

    Washington D.C., District of Columbia

  • Capital Medical Associates, PC CRS

    Washington D.C., District of Columbia

  • Infectious Diseases Clinic, Washington DC Veterans Affairs Medical Center CRS

    Washington D.C., District of Columbia

  • Malcom Randall VA Medical Center CRS

    Gainesville, Florida

  • AHF-The Kinder Medical Group CRS

    Miami, Florida

  • The University of Miami AIDS Clinical Research Unit (ACRU) CRS

    Miami, Florida

  • University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS

    Miami, Florida

  • AHF - South Beach CRS

    Miami, Florida

  • Orlando Immunology Center CRS

    Orlando, Florida

  • Community AIDS Network/Comprehensive Care Clinic CRS

    Sarasota, Florida

  • Florida Department of Health - Hillsborough County

    Tampa, Florida

  • AIDS Research and Treatment Center of the Treasure Coast CRS

    Vero Beach, Florida

  • The Ponce de Leon Center CRS

    Atlanta, Georgia

  • Augusta University Research Institute, Inc. CRS

    Augusta, Georgia

  • Northwestern University CRS*

    Chicago, Illinois

  • Rush University CRS*

    Chicago, Illinois

  • UIC Project WISH CRS

    Chicago, Illinois

  • Indiana University Infectious Diseases Research CRS

    Indianapolis, Indiana

  • Department of Internal Medicine, University of Iowa Hospitals & Clinics CRS

    Iowa City, Iowa

  • Bluegrass Care Clinic/University of Kentucky Research Foundation CRS

    Lexington, Kentucky

  • 550 Clinic -University of Louisville CRS

    Louisville, Kentucky

  • Tulane - Louisiana Community AIDS Research Program (T-LaCARP) CRS

    New Orleans, Louisiana

  • Johns Hopkins University CRS*

    Baltimore, Maryland

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.